103.87

0.88% -0.92

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is traded at $103.87, with a volume of 827.62K. It is down -0.88% in the last 24 hours and up +14.39% over the past month. Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Previous Close:

$104.79

Open:

$106.12

24h Volume:

827.62K

Relative Volume:

0.87

Market Cap:

$5.68B

Revenue:

$1.34M

Net Income/Loss:

$-173.66M

P/E Ratio:

-25.10

EPS:

-4.1385

Net Cash Flow:

$-130.49M

1W Performance:

-1.64%

1M Performance:

+14.39%

6M Performance:

+98.49%

1Y Performance:

+376.69%

1-Day Range:

$102.63

$106.28

1-Week Range:

$100.03

$107.99

52-Week Range:

$18.08

$107.99

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

929-999-4055

Address

7 TIMES SQUARE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

DNTH's Discussions on Twitter

Compare DNTH vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNTH Dianthus Therapeutics Inc	103.87	5.68B	1.34M	-173.66M	-130.49M	-4.1385
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-10-26	Upgrade	Raymond James	Outperform → Strong Buy
Oct-14-25	Initiated	Truist	Buy
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-26-24	Initiated	Robert W. Baird	Outperform
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy
Feb-15-24	Initiated	Stifel	Buy
Dec-26-23	Initiated	Jefferies	Buy
Nov-22-23	Initiated	Wedbush	Outperform
Oct-30-23	Initiated	Guggenheim	Buy
Sep-28-23	Initiated	Raymond James	Outperform
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-06-22	Upgrade	Goldman	Neutral → Buy
Aug-20-21	Resumed	Goldman	Neutral
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-21	Reiterated	B. Riley Securities	Buy
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight
Jun-15-21	Initiated	BTIG Research	Buy
May-18-21	Initiated	B. Riley Securities	Buy
Jan-07-21	Initiated	Mizuho	Buy
Jun-08-20	Upgrade	Goldman	Neutral → Buy
Mar-25-19	Downgrade	Goldman	Buy → Neutral
Mar-15-19	Initiated	Raymond James	Outperform

View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

06:15 AM

Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

06:15 AM

02:36 AM

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

02:36 AM

Jul 24, 2026

DNTH|Dianthus Therapeutics Inc|Price:103.870|Chg%:-0.920 - TradingKey

Jul 24, 2026

Jul 23, 2026

Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Jul 23, 2026

Jul 20, 2026

Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN

Jul 20, 2026

Dianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trial - TIKR.com

Jul 20, 2026

Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – FWB:87E - TradingView

Jul 20, 2026

Jul 17, 2026